Literature DB >> 35322200

Gene expression changes following chronic antipsychotic exposure in single cells from mouse striatum.

Anthony Abrantes1, Paola Giusti-Rodriguez2, Patrick F Sullivan3,4,5, Rainbo Hultman6,7, NaEshia Ancalade3, Shadia Sekle3, Marcus L Basiri8, Garret D Stuber9.   

Abstract

Schizophrenia is an idiopathic psychiatric disorder with a high degree of polygenicity. Evidence from genetics, single-cell transcriptomics, and pharmacological studies suggest an important, but untested, overlap between genes involved in the etiology of schizophrenia and the cellular mechanisms of action of antipsychotics. To directly compare genes with antipsychotic-induced differential expression to genes involved in schizophrenia, we applied single-cell RNA-sequencing to striatal samples from male C57BL/6 J mice chronically exposed to a typical antipsychotic (haloperidol), an atypical antipsychotic (olanzapine), or placebo. We identified differentially expressed genes in three cell populations identified from the single-cell RNA-sequencing (medium spiny neurons [MSNs], microglia, and astrocytes) and applied multiple analysis pipelines to contextualize these findings, including comparison to GWAS results for schizophrenia. In MSNs in particular, differential expression analysis showed that there was a larger share of differentially expressed genes (DEGs) from mice treated with olanzapine compared with haloperidol. DEGs were enriched in loci implicated by genetic studies of schizophrenia, and we highlighted nine genes with convergent evidence. Pathway analyses of gene expression in MSNs highlighted neuron/synapse development, alternative splicing, and mitochondrial function as particularly engaged by antipsychotics. In microglia, we identified pathways involved in microglial activation and inflammation as part of the antipsychotic response. In conclusion, single-cell RNA sequencing may provide important insights into antipsychotic mechanisms of action and links to findings from psychiatric genomic studies.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35322200     DOI: 10.1038/s41380-022-01509-7

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  67 in total

Review 1.  Genetic architectures of psychiatric disorders: the emerging picture and its implications.

Authors:  Patrick F Sullivan; Mark J Daly; Michael O'Donovan
Journal:  Nat Rev Genet       Date:  2012-07-10       Impact factor: 53.242

2.  Recurrence risks for schizophrenia in a Swedish national cohort.

Authors:  Paul Lichtenstein; Camilla Björk; Christina M Hultman; Edward Scolnick; Pamela Sklar; Patrick F Sullivan
Journal:  Psychol Med       Date:  2006-07-25       Impact factor: 7.723

3.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.

Authors:  Patrick F Sullivan; Kenneth S Kendler; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-12

4.  The global costs of schizophrenia.

Authors:  Martin Knapp; Roshni Mangalore; Judit Simon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

Review 5.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Authors:  Sukanta Saha; David Chant; John McGrath
Journal:  Arch Gen Psychiatry       Date:  2007-10

6.  Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.

Authors:  Paul Lichtenstein; Benjamin H Yip; Camilla Björk; Yudi Pawitan; Tyrone D Cannon; Patrick F Sullivan; Christina M Hultman
Journal:  Lancet       Date:  2009-01-17       Impact factor: 79.321

Review 7.  Genetic architecture: the shape of the genetic contribution to human traits and disease.

Authors:  Nicholas J Timpson; Celia M T Greenwood; Nicole Soranzo; Daniel J Lawson; J Brent Richards
Journal:  Nat Rev Genet       Date:  2017-12-11       Impact factor: 53.242

8.  Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders.

Authors:  Hoang T Nguyen; Julien Bryois; April Kim; Amanda Dobbyn; Laura M Huckins; Ana B Munoz-Manchado; Douglas M Ruderfer; Giulio Genovese; Menachem Fromer; Xinyi Xu; Dalila Pinto; Sten Linnarsson; Matthijs Verhage; August B Smit; Jens Hjerling-Leffler; Joseph D Buxbaum; Christina Hultman; Pamela Sklar; Shaun M Purcell; Kasper Lage; Xin He; Patrick F Sullivan; Eli A Stahl
Journal:  Genome Med       Date:  2017-12-20       Impact factor: 11.117

9.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Authors:  Antonio F Pardiñas; Peter Holmans; Andrew J Pocklington; Valentina Escott-Price; Stephan Ripke; Noa Carrera; Sophie E Legge; Sophie Bishop; Darren Cameron; Marian L Hamshere; Jun Han; Leon Hubbard; Amy Lynham; Kiran Mantripragada; Elliott Rees; James H MacCabe; Steven A McCarroll; Bernhard T Baune; Gerome Breen; Enda M Byrne; Udo Dannlowski; Thalia C Eley; Caroline Hayward; Nicholas G Martin; Andrew M McIntosh; Robert Plomin; David J Porteous; Naomi R Wray; Armando Caballero; Daniel H Geschwind; Laura M Huckins; Douglas M Ruderfer; Enrique Santiago; Pamela Sklar; Eli A Stahl; Hyejung Won; Esben Agerbo; Thomas D Als; Ole A Andreassen; Marie Bækvad-Hansen; Preben Bo Mortensen; Carsten Bøcker Pedersen; Anders D Børglum; Jonas Bybjerg-Grauholm; Srdjan Djurovic; Naser Durmishi; Marianne Giørtz Pedersen; Vera Golimbet; Jakob Grove; David M Hougaard; Manuel Mattheisen; Espen Molden; Ole Mors; Merete Nordentoft; Milica Pejovic-Milovancevic; Engilbert Sigurdsson; Teimuraz Silagadze; Christine Søholm Hansen; Kari Stefansson; Hreinn Stefansson; Stacy Steinberg; Sarah Tosato; Thomas Werge; David A Collier; Dan Rujescu; George Kirov; Michael J Owen; Michael C O'Donovan; James T R Walters
Journal:  Nat Genet       Date:  2018-02-26       Impact factor: 38.330

10.  Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders.

Authors:  Tarjinder Singh; Mitja I Kurki; David Curtis; Shaun M Purcell; Lucy Crooks; Jeremy McRae; Jaana Suvisaari; Himanshu Chheda; Douglas Blackwood; Gerome Breen; Olli Pietiläinen; Sebastian S Gerety; Muhammad Ayub; Moira Blyth; Trevor Cole; David Collier; Eve L Coomber; Nick Craddock; Mark J Daly; John Danesh; Marta DiForti; Alison Foster; Nelson B Freimer; Daniel Geschwind; Mandy Johnstone; Shelagh Joss; Georg Kirov; Jarmo Körkkö; Outi Kuismin; Peter Holmans; Christina M Hultman; Conrad Iyegbe; Jouko Lönnqvist; Minna Männikkö; Steve A McCarroll; Peter McGuffin; Andrew M McIntosh; Andrew McQuillin; Jukka S Moilanen; Carmel Moore; Robin M Murray; Ruth Newbury-Ecob; Willem Ouwehand; Tiina Paunio; Elena Prigmore; Elliott Rees; David Roberts; Jennifer Sambrook; Pamela Sklar; David St Clair; Juha Veijola; James T R Walters; Hywel Williams; Patrick F Sullivan; Matthew E Hurles; Michael C O'Donovan; Aarno Palotie; Michael J Owen; Jeffrey C Barrett
Journal:  Nat Neurosci       Date:  2016-03-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.